Utama › Hipertensi Pulmonari › Illinois
Kajian klinikal Hipertensi Pulmonari di Illinois
6 kajian untuk Hipertensi Pulmonari sedang mencari peserta di lokasi di Illinois.
Bandar di Illinois
Teks kajian rasmi (Bahasa Inggeris)
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
- Northwestern University, Chicago
- University of Illinois Health, Chicago
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06911632A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
- Northwestern University, Chicago
Mengambil pesertaFasa 3
Umur 18 hingga 80 · Semua jantina · Dikemas kini 2 Sep 2026 · NCT07285655A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
- Clinical Research Site, Chicago
Mengambil pesertaFasa 2
Umur 18 hingga 85 · Semua jantina · Dikemas kini 2 Sep 2026 · NCT07333183DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Northwestern University, Chicago
- Loyola University Medical Center, Maywood
- Advocate Christ Medical Center, Oak Lawn
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Ogo 2026 · NCT06388421Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG
- Prairie Cardiovascular, O'Fallon
- Prairie Education & Research Cooperative, Springfield
- St Johns Hospital, Springfield, Springfield
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Jun 2026 · NCT07087613Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
- University of Chicago, Chicago
- Advocate Health & Hospitals Corporation, Oakbrook Terrace
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Jun 2026 · NCT06526195Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.